Moderna and Carisma collaborate to develop in-vivo engineered CAR-M for oncology

Moderna Inc and Carisma Therapeutics Inc yesterday announced that the two companies have entered into a strategic collaboration agreement to discover, develop and commercialise in-vivo engineered Chimeric Antigen Receptor Monocyte (CAR-M) therapeutics for the treatment of cancer.

Speaking in this regard, Stephen Hoge, President, Moderna, said that this collaboration exemplies our strategy to partner with companies with deep biological expertise while leveraging Moderna’s core mRNA and LNP capabilities to further expand the reach of Moderna’s technology.

“Moderna’s deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages,” said Steven Kelly, President and Chief Executive Officer, Carisma.

He added, “In-vivo delivery directly to monocytes and macrophages enables an on-the-shelf therapeutic approach that uses the patients’ own cells to provide a truly personalised treatment….”